This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.

Start Date01 Mar 2025

Sponsor / Collaborator

George Washington University

ChiCTR2500097097

/ SuspendedPhase 4IIT

The Efficacy of Liposomal Bupivacaine Local Infiltration for Postoperative Analgesia in Elderly Patients Undergoing Lumbar Surgery

Start Date25 Feb 2025

Sponsor / Collaborator-

ChiCTR2500097068

/ SuspendedNot ApplicableIIT

Clinical study of Liposomal Bupivacaine in preoperative analgesia in elderly patients with hip fracture

Start Date15 Feb 2025

Sponsor / Collaborator

Suizhou Central Hospital

100 Clinical Results associated with Bupivacaine liposome

100 Translational Medicine associated with Bupivacaine liposome

100 Patents (Medical) associated with Bupivacaine liposome

677

Literatures (Medical) associated with Bupivacaine liposome

01 Apr 2025·Surgery for Obesity and Related Diseases

Liposomal bupivacaine for sleeve gastrectomy is associated with improved opioid outcomes and lower odds of opioid use disorder: claims-based analysis

Article

Author: Kakoty, Swapnabir ; Gould, Jon ; Sandor, Andras ; Lin, Jennifer H ; DiGiorgi, Mary ; LeBlanc, Karl A. ; LeBlanc, Karl A ; Lin, Jennifer H.

BACKGROUNDPatients undergoing bariatric surgery may be at increased risk for postsurgical opioid dependence, highlighting a need for opioid-sparing anesthesia.OBJECTIVESLiposomal bupivacaine (LB), a prolonged release formulation of bupivacaine, may improve postoperative pain management and reduce postsurgical opioid use. This retrospective claims-database study investigated the effects of LB versus non-LB analgesia on opioid use and healthcare resource utilization (HCRU) in patients receiving laparoscopic sleeve gastrectomy (SG).SETTINGRetrospective study using the IQVIA linkage claims database.METHODSData from patients aged ≥18 years and free of opioid prescriptions within the prior 6 months undergoing inpatient laparoscopic SG between January 1, 2016, and December 31, 2019, were analyzed. Outcomes included perioperative opioid use in oral morphine milligram equivalents (MMEs), opioid-related adverse events (ORAEs), postdischarge HCRU, continued (>2 weeks to 3 months postdischarge) and persistent (4-6 months postdischarge) opioid use, and opioid use disorder (OUD) at 6 months.RESULTSOf 4298 patients (2149 in each cohort), LB was associated with significantly fewer perioperative opioids (100.53 versus 155.48 MMEs; mean difference, -54.95 [95% confidence interval (CI), -64.46, -45.45]; P < .0001), lower rates of in-hospital ORAEs (9.63% versus 13.82%; odds ratio [OR], .67 [95% CI, .55, .80]; P < .0001), significantly lower incidence of OUD (.09% versus .51%; OR, .18 [95% CI, .04, .82]; P = .026), shorter hospital length of stay (P = .0008), and significantly lower odds of 30-day postdischarge hospital readmissions (P = .025) versus non-LB analgesia.CONCLUSIONSLB reduced opioid use, in-hospital ORAEs, OUD, and hospital readmissions after laparoscopic SG.

01 Mar 2025·Journal of Shoulder and Elbow Surgery

Single-shot interscalene block with liposomal bupivacaine vs. non-liposomal bupivacaine in shoulder arthroplasty

Article

Author: Lorentz, Samuel ; Levin, Jay M ; Poehlein, Emily ; Hurley, Eoghan T ; Anakwenze, Oke ; Warren, Eric ; Green, Cynthia L ; Bullock, W Michael ; Gadsden, Jeff C ; Klifto, Christopher S ; Mills, Frederic B ; Crook, Bryan S

BACKGROUNDRegional anesthesia is a valuable component of multimodal pain control in total shoulder arthroplasty (TSA), and multiple interscalene block anesthetic options exist, including nonliposomal interscalene bupivacaine (NLIB) and liposomal interscalene bupivacaine (LIB). The purpose of this study was to compare pain control and opioid consumption within 48 hours postoperation in those undergoing TSA with either LIB or NLIB.METHODSThis was a retrospective cohort study at a single academic medical center including consecutive patients undergoing inpatient (>23-hour hospitalization) primary anatomic or reverse TSA from 2016 to 2020 who received either LIB or an NLIB for perioperative pain control. Perioperative patient outcomes were collected including pain levels and opioid usage, as well as 30- and 90-day emergency department (ED) visits or readmissions. The primary outcome was postoperative pain and opioid use.RESULTSOverall, 489 patients were included in this study (316 LIB and 173 NLIB). Pain scores at 3, 6, 12, and 48 hours postoperatively were not statistically significantly different (P > .05 for all). However, the LIB group had improved pain scores at 24 and 36 hours postoperation (P < .05 all). There was no difference in the incidence of severe postoperative pain, defined as a 9 or 10 numeric rating scale-11 score, between the 2 anesthesia groups after adjusting for preoperative pain and baseline opioid use (odds ratio 1.25, 95% confidence interval 0.57-2.74; P = .57). Overall, 99 of 316 patients receiving LIB (31.3%) did not require any postoperative opioids compared with 38 of 173 receiving NLIB (22.0%); however, this difference was not statistically significant after adjusting for prior opioid use and preoperative pain (P = .33). No statistically significant differences in postoperative total morphine equivalents or mean daily morphine equivalents consumed between the groups were found during their hospital stays (P > .05 for both). Finally, no significant differences were found in 30- and 90-day ED visits or readmission rates (all P > .05).CONCLUSIONLIB and NLIB demonstrated differences in patient-reported pain scores at 24 and 36 hours postoperation, although these did not reach clinical significance. There were no statistically significant differences in opioid consumption during the hospital stay, including opioid use, total morphine equivalents, and daily mean morphine equivalents consumed during the hospital stay. Additionally, no differences were observed in 30- and 90-day ED visits or readmission rates.

01 Mar 2025·Journal of Clinical Anesthesia

Letter to the editor regarding “Recovery quality of transversus abdominis plane block with liposomal bupivacaine after cesarean delivery: A randomized trial”

Letter

Author: Guo, Yan-Hua ; Wang, Dan-Feng ; Xue, Fu-Shan

News (Medical) associated with Bupivacaine liposome

13 Apr 2021

·www.globenewswire.com

Liquidia Corporation Announces $21.7 Million Private Placement

RESEARCH TRIANGLE PARK, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has entered into a common stock purchase agreement with certain institutional, accredited investors for the private placement of 8,626,037 shares of common stock at a purchase price of $2.52 per share, the closing price per share of common stock on April 12, 2021. The private placement is expected to close today and yield gross proceeds of approximately $21.7 million. The investor group was led by Caligan Partners LP and includes participation by existing directors Paul Manning and Roger Jeffs. Upon closing, David Johnson, a Partner and Co-Founder of Caligan Partners LP, will be appointed to the board of directors of Liquidia Corporation as a Class II Director and a member of the Audit Committee. Previously, Mr. Johnson worked at The Carlyle Group as Managing Director and at Morgan Stanley as Vice President in the Principal Investments area. Mr. Johnson was previously a director of AMAG Pharmaceuticals. Stephen Bloch, M.D., Chairman of the Liquidia Board of Directors, said: “Adding David to the Board further strengthens our abilities to navigate financial markets and advise Liquidia with the short and long term in mind. We look forward to bringing his experiences to bear in future discussions.” David Johnson said: “We are excited to support Liquidia’s commitment to bring novel therapies to market for patients with pulmonary arterial hypertension (PAH). Caligan believes that LIQ861 will be the best inhaled option to treat PAH because of its convenience and ability to safely provide symptomatic relief at higher dosage levels than existing inhaled treprostinil therapies. We are also excited about Liquidia’s recent announcement that its subcutaneous Treprostinil Injection will soon be available to PAH patients. We have tremendous confidence in Damian deGoa and the Liquidia team to execute on their strategic plan and look forward to working closely with them during their next stage of growth.” Damian deGoa, Chief Executive Officer of Liquidia, said: “We are fortunate to include David Johnson on the board and to bring smart, committed investors into Liquidia. This financing builds on several steps taken during the last three months to strengthen our balance sheet and position the company for an exciting future.” Net proceeds from this private placement are expected to strengthen commercial capability for the introduction of LIQ861 and the subcutaneous administration of Treprostinil Injection, enable growth initiatives, and provide support general corporate purposes. The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Liquidia has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the shares of common stock to be issued and sold in the private placement no later than the 180th day after the closing of the private placement. Any offering of the securities under the registration statement will only be made by means of a prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About LIQ861 LIQ861 is an investigational inhaled dry powder formulation of treprostinil designed using Liquidia’s PRINT® technology with the goal of enhancing deep-lung delivery using a convenient, palm-sized dry powder inhaler for the treatment of pulmonary arterial hypertension (PAH). PRINT® technology enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for optimal deposition in the lung following oral inhalation. Liquidia believes LIQ861 can overcome the limitations of current inhaled therapies and has the potential to maximize the therapeutic benefits of treprostinil in treating PAH by safely delivering higher doses into the lungs. Liquidia has completed an open-label, multi-center phase 3 clinical study of LIQ861 in patients diagnosed with PAH known as INSPIRE, or In vestigation of the S afety and P harmacology of Dry Powder I nhalation of T re prostinil. About Treprostinil Injection Treprostinil Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration. Treprostinil Injection contains the same active ingredient, same strengths, same dosage form and same inactive ingredients as Remodulin® (treprostinil), and is offered to patients and physicians with the same level of service and support, but at a lower price than the branded drug. Liquidia PAH promotes the appropriate use of Treprostinil Injection for the treatment of PAH in the United States in partnership with its commercial partner, who holds the Abbreviated New Drug Application (ANDA) with the FDA. About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies is developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of PAH, and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as Treprostinil Injection. Liquidia Corporation is headquartered in Research Triangle Park, NC. For more information, please visit . Cautionary Statements Regarding Forward-Looking Statements This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related anticipated submission contents and timelines, including our potential response to the Complete Response Letter received in November 2020, the potential for eventual FDA approval of the NDA for LIQ861, the timeline or outcome related to our patent litigation pending in the U.S. District Court for the District of Delaware or its inter partes review with the PTAB, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, including the risk that the expected benefits and synergies from the Merger Transaction are not realized, the impact of the coronavirus (COVID-19) outbreak on our Company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information Investors & Media: Jason Adair Vice President, Corporate Development and Strategy 919.328.4400 jason.adair@liquidia.com

CollaborateAcquisition

31 Mar 2021

·www.biospace.com

Flexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative Pain

FX301 is a locally administered NaV1.7 inhibitor (funapide) formulated for extended release in a proprietary thermosensitive hydrogel Proof-of-concept trial will evaluate safety and tolerability of FX301 administered as a peripheral analgesic nerve block in patients undergoing bunionectomy; initial data anticipated later this year BURLINGTON, Mass., March 31, 2021 (GLOBE NEWSWIRE) --Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in a Phase 1b proof-of-concept trial evaluating the safety and tolerability of FX301 administered as a single-dose, popliteal fossa block (a commonly used nerve block in foot and ankle-related surgeries) in patients undergoing bunionectomy. “There are approximately seven million orthopedic surgical procedures performed in the United States each year, and with many of those patients using opioids after surgery, there is a substantial need for non-opioid post-operative pain management,” said Michael Clayman, M.D., President and Chief Executive Officer of Flexion. “FX301 has the potential to deliver extended pain relief while preserving motor function which we believe could provide improved patient comfort, reduce the need for opioids, allow for earlier ambulation and physical therapy, and enable patients to leave the facility or hospital sooner following surgery.” The Phase 1b randomized, double-blind, placebo-controlled study will be conducted in two parts beginning with a single ascending dose portion which will investigate FX301 at low and high doses of funapide administered at two volumes in four cohorts of patients undergoing bunionectomy. A total of 48 patients (12 patients per cohort), will be randomized to receive either FX301 or placebo. A Safety Monitoring Committee will review data from each dose cohort before the study escalates into higher doses. The data from the single ascending dose portion of the trial will be reviewed and a decision made regarding expanding a selected dose and volume cohort by another 36 patients. This would support broader understanding of the safety and efficacy in that cohort. FX301 represents a potential first-in-class analgesic nerve block agent. In a validated preclinical model of post-operative pain, FX301 administered as a peripheral nerve block demonstrated analgesic effect beginning at 1 hour post-dosing compared to placebo and significantly greater analgesic effect compared to liposomal bupivacaine at 36 hours post-dosing. Data from the study also indicated that treatment with FX301 did not significantly affect total walking distance in animals at 2 and 24 hours post-injection, whereas animals treated with liposomal bupivacaine experienced a significant reduction in total walking distance at those time points. The company anticipates sharing data from the Phase 1b trial of FX301 in late 2021. About FX301 FX301 is an investigational locally administered NaV1.7 inhibitor known as funapide, formulated for extended release in a thermosensitive hydrogel. The initial development of FX301 is intended to support administration as a peripheral analgesic nerve block for control of post-operative pain. Flexion believes FX301 has the potential to provide effective pain relief for at least three to five days while preserving motor function. About Flexion Therapeutics Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA, the most common form of arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Please visit flexiontherapeutics.com. Forward-Looking Statements This press release contains forward-looking statements that are based on the current expectations and beliefs of Flexion. Statements in this press release regarding matters that are not historical facts, including, but not limited to, statements relating to the future of Flexion; timing and plans with respect to the Phase 1b clinical trial of FX301; and the potential therapeutic and other benefits of FX301, are forward looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the fact that the impacts and expected duration of the COVID-19 pandemic are uncertain and rapidly changing; the risk that we may not be able to maintain and enforce our intellectual property, including intellectual property related to FX301; risks related to clinical trials, including potential delays, safety issues or negative results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 10, 2021 and subsequent filings with the SEC. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of the statements. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Contacts: Scott Young Vice President, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 syoung@flexiontherapeutics.com Julie Downs Associate Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7137 jdowns@flexiontherapeutics.com

CollaborateFirst in Class

09 Mar 2021

·www.globenewswire.com

Liquidia Corporation to Host 2020 Financial

RESEARCH TRIANGLE PARK, N.C., March 09, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that 2020 financial results will be reported on Tuesday, March 23, 2021. The company will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and provide a corporate update. The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 5167825. A live and archived webcast of the call will be available on the Events & Presentations page of Liquidia’s website. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT technology. The Company operates through two subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies is developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH), and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. Liquidia PAH, LLC provides commercialization for rare disease pharmaceutical products, such as Treprostinil Injection, Sandoz Inc.’s first-to-file, generic treprostinil for PAH. Liquidia Corporation is headquartered in Research Triangle Park, NC. For more information, please visit . Contact InformationMedia & Investors:Jason AdairVice President, Corporate Development and Strategy919.328.4400jason.adair@liquidia.com

Financial Statement

100 Deals associated with Bupivacaine liposome

External Link

KEGG	Wiki	ATC	Drug Bank
D07552	Bupivacaine liposome	N01BB01	DB00297

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	United States	Pacira Biosciences, Inc.	28 Oct 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04300231 (CTgov)	Phase 3	Pain, Postoperative	160	/hydromorphone 0.05mg/ml+bupivacaine (Thoracic Epidural)	xggkenjzbg(fmfmnsqsec) = djyypxvoff gbybizcatu (lcwihnjctv, kedfmneood - fbzcpfylzj) View more	-	10 Feb 2025
				injectable saline+Liposomal bupivacaine+bupivacaine (Rectus Sheath Block)	xggkenjzbg(fmfmnsqsec) = pmeryddkvz gbybizcatu (lcwihnjctv, ukhnfmwnup - tpigdezijh) View more
NCT04777591 (CTgov)	Phase 4	Pain, Postoperative	117	Bupivacain (Control - Plain Bupivacaine)	zepzedbgot(itqkpqohwl) = chefwzjrtx guvcpghvzw (agbkgjaccw, nhewpvncfe - myhooduhvc) View more	-	23 Aug 2024
				Liposomal bupivacaine TAP block+bupivacain (Experimental - Liposomal Bupivacaine)	zepzedbgot(itqkpqohwl) = qacryqhqrz guvcpghvzw (agbkgjaccw, hsbzdxizkw - hpaubsdtmw) View more
NCT03496610 (CTgov)	Phase 4	Pain, Postoperative	44	QL Block (Quadratus Lumborum (QL) Block)	wkezaojfvc(ijdzmuvufj) = qmlmksqjde tuwzjxgful (sjbbnxypmr, qhyescfyyg - jkbfrspaxr) View more	-	05 Mar 2024
				Liposomal Bupivicaine (Surgical Wound Infiltration)	wkezaojfvc(ijdzmuvufj) = sacpvsrumt tuwzjxgful (sjbbnxypmr, tskewqxgzh - mceqtbgsit) View more
NCT05005260 (CTgov)	Phase 4	occlusions \| Pain, Postoperative	88	Liposomal bupivacaine+Bupivacaine Hcl (Liposomal Bupivacaine Single-shot Interscalene Blockade)	gpaaopncxs(eludyrnxov) = okpmrceiid ntbagpmbln (itsxxqtxuk, syzusbuzhv - paxpmdjopi) View more	-	18 Dec 2023
				Bupivacaine HCl (Continuous Interscalene Nerve Blockade)	gpaaopncxs(eludyrnxov) = zyutfqjpnp ntbagpmbln (itsxxqtxuk, epszhuhwri - zfthagcemj) View more
NCT03502018 (HEAT, CTgov)	Phase 4	Femoral Neck Fractures	50	Saline (Saline)	wctbcmveuw(afqaooeiwv) = ntbkaoiwvz ogavghzpli (vhkxmlsqte, wuhldenpoo - ipxbrgyejd) View more	-	18 Nov 2023
				Bupivacaine liposome (Bupivacaine Liposome)	wctbcmveuw(afqaooeiwv) = pmprwwvjcz ogavghzpli (vhkxmlsqte, yjkmfzsnqo - jhgjucbypp) View more
NCT03972397 (CTgov)	Phase 4	Pain, Postoperative	20	Patient-controlled analgesia (PCA)+Bupivacaine liposomal injectable suspension (Intercostal Nerve Cryoablation Plus SOC Pain Control)	lxoeyndeha(mvfpokmvrl) = lafkgplfdj qqqpdfcico (zbtthkpcwh, ifukvhtykm - pqjutkwexb) View more	-	02 Nov 2023
				Patient-controlled analgesia (PCA)+Bupivacaine liposomal injectable suspension (Standard of Care (SOC) Pain Control)	lxoeyndeha(mvfpokmvrl) = zoaflouzrf qqqpdfcico (zbtthkpcwh, rhqhuargfu - pgplwmeubp) View more
NCT03887650 (CTgov)	Phase 4	Pain, Postoperative \| Shoulder arthritis	90	Liposomal Bupivicaine 1.3% (Liposomal Bupivacaine 1.3%)	yloarrmwoc(glepiinhig) = rwzygqyljg umngxwsgow (hxqnozxyay, sahlicnpan - zovhfryrmv) View more	-	15 Sep 2023
				Bupivacaine 0.5% (Bupivacaine 0.5% With Adjuncts)	yloarrmwoc(glepiinhig) = sqmzrqyhco umngxwsgow (hxqnozxyay, rbnayqhfmm - cfrrdoxhca) View more
NCT04749797 (CTgov)	Phase 4	Pain \| Anesthesia	11	Bupivacaine Injection (Bupivacaine)	(nwqstrorgx) = tgpmeuyfqg rlumjjgtgh (gttkpkhrvy, szxdxijpht - xxcuvqqmla) View more	-	13 Sep 2023
				Saline (Saline Group)	(nwqstrorgx) = ugwkkpbhrp rlumjjgtgh (gttkpkhrvy, woweqgsqvz - hduwpxwibd) View more
NCT03702621 (CTgov)	Phase 3	-	90	liposomal Bupivacaine (Liposomal Bupivacaine)	zlevnmyvoy(dsxmvncagf) = ejggoucjvo xgiyjofcti (ujibqhakgi, ueyrthllzd - kiwqzgxubb) View more	-	17 May 2023
				Bupivacaine Hydrochloride (Standard Bupivacaine)	zlevnmyvoy(dsxmvncagf) = ftaagfshfa xgiyjofcti (ujibqhakgi, jztbqlbqfb - plqxrujhms) View more
NCT03922620 (CTgov)	Phase 4	Anesthesia \| Opioid abuse \| Acute Pain	1	Liposomal bupivacaine (Liposomal Bupivacaine Group)	tivzaomygc(cqgtyvzeii) = kyuqmgnkua kryqhxcyto (bgiegjqfmo, vzusbtptaw - bmmanifbph) View more	-	23 Feb 2023
				Peripheral Nerve Block (Peripheral Nerve Block Group)	hmjlntriwi(ciktdkwsxr) = zwqagqrgai ldlohxwtxx (prvxmjjuna, cczznoqezb - gbbdiiafwq) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis